$heff's $tation of $tocks & $olid DD

[dumchit]

AMRN Jason Npododano talked to AMRN this was on his twitter

Jason Napodano, CFA

Ok - just spoke to $AMRN -->Mgt has not seen the final rejection letter yet, but was firm in their stance that the words "final rejection" are doubly misleading. Fist off, the letter is not "final", they will apeal. Secondly, there's no "rejection" of the IP. AMRN has filed "hundreds" of patents around MARINE and ANCHOR. This is just one of many. The issue is with data exclusivity. A company in Japan has previously studied the drug in 200-500mg population. MARINE was >500mg population. USPTO sees this as the "same" patients. AMRN disagrees, and will apeal. Long story short, there's nothing in this rejection that puts the IP at risk, still many applications pending and patents active, including applications around ANCHOR.